MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on November 21, 2005; DOI: 10.1124/mol.105.018127

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.018127v1
69/3/823    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brochu, R. M.
Right arrow Articles by Priest, B. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brochu, R. M.
Right arrow Articles by Priest, B. T.


Received for publication August 17, 2005.
Revised October 10, 2005.
Accepted for publication November 16, 2005.

Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats

Richard M. Brochu 1, Ivy E. Dick 2, Jason W. Tarpley 3, Erin McGowan 1, David Gunner 4, James Herrington 5, Pengcheng P. Shao 5, Dong Ok 1, Chunshi Li 1, William H Parsons 1, Gary L. Stump 1, Christopher P. Regan 1, Joseph J Lynch 1, Kathryn A. Lyons 1, Owen B. McManus 1, Sam A Clark 1, Zahid Ali 6, Gregory J Kaczorowski 1, William J Martin 1, Birgit T. Priest 1*

1 Merck Research Laboratories 2 John's Hokins University 3 UCLA 4 Imperial College London 5 Merck & Co. 6 Glaxo Smith Kline

* Address correspondence to: E-mail: birgit_priest{at}merck.com

Abstract

Several sodium channel blockers are used clinically to treat neuropathic pain. However, many patients fail to achieve adequate pain relief from these highly brain-penetrant drugs because of dose-limiting CNS side effects. Here we describe the functional properties of Trans-N-{[2'-(aminosulfonyl)biphenyl-4-yl]methyl}-N-methyl-N'-[4-(trifluoromethoxy)benzyl]cyclopentane-1,2-dicarboxamide (CDA54), a peripherally acting sodium channel blocker. In whole cell electrophysiology assays, CDA54 blocked the inactivated states of hNaV1.7 and hNaV1.8, two channels of the peripheral nervous system implicated in nociceptive transmission, with affinities of 0.25 µM and 0.18 µM, respectively. CDA54 displayed similar affinities for the tetrodotoxin-resistant Na+ current in small diameter mouse dorsal root ganglion neurons. Peripheral nerve injury causes spontaneous electrical activity in normally silent sensory neurons. CDA54 inhibited these injury-induced spontaneous action potentials at concentrations 10-fold below those required to block normal A- and C-fiber conduction. Consistent with the selective inhibition of injury-induced firing, CDA54 (10 mg kg-1 p.o.) significantly reduced behavioral signs of neuropathic pain in two nerve injury models, whereas the same dose of CDA54 did not affect acute nociception or motor coordination. In anesthetized dogs, CDA54, at plasma concentrations of 6.7 µM, had no effect on cardiac electrophysiological parameters including conduction. Thus, the peripheral nerve sodium channel blocker CDA54 selectively inhibits sensory nerve signaling associated with neuropathic pain.


Key words: Sodium, Local anesthetics


This article has been cited by other articles:


Home page
 J. Gen. Physiol.Home page
G. J. Kaczorowski, O. B. McManus, B. T. Priest, and M. L. Garcia
Ion Channels as Drug Targets: The Next GPCRs
J. Gen. Physiol., April 28, 2008; 131(5): 399 - 405.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. McGaraughty, K. L. Chu, M. J. C. Scanio, M. E. Kort, C. R. Faltynek, and M. F. Jarvis
A Selective Nav1.8 Sodium Channel Blocker, A-803467 [5-(4-Chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], Attenuates Spinal Neuronal Activity in Neuropathic Rats
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1204 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. F. Jarvis, P. Honore, C.-C. Shieh, M. Chapman, S. Joshi, X.-F. Zhang, M. Kort, W. Carroll, B. Marron, R. Atkinson, et al.
From the Cover: A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat
PNAS, May 15, 2007; 104(20): 8520 - 8525.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. I. Ilyin, J. D. Pomonis, G. T. Whiteside, J. E. Harrison, M. S. Pearson, L. Mark, P. I. Turchin, S. Gottshall, R. B. Carter, P. Nguyen, et al.
Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1083 - 1093.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics